Study on the Efficacy and Safety of Adefovir Dipivoxil Treatment in Post–Liver Transplant Patients With Hepatitis B Virus Infection and Lamivudine-Resistant Hepatitis B Virus

Bárcena, Rafael; Campo, Salvatore; Moraleda, Gloria; Casanovas, Teresa; Prieto, M.; Buti, María; Moreno, José María Ruiz; Cuervas, V.; Fraga, Enrique; Mata, Manuel de la; Otero, Alejandra; Delgado, Marcial; Loinaz, Carmelo; Barrios, C.; Dieguez, Maria Luisa Gonzalez; Mas, Antoni; Sousa, J.M.; Herrero, J.I.; Muñoz, Raquel; Avilés, J.; González, Antonio; Rueda, Magdalena

doi:10.1016/j.transproceed.2005.10.061

Cited by 32 publications

(18 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are no data to confirm lower rates of transmission with combined treatment 2,14 . More recently, the use of tenofovir and entecavir as prophylactic antivirals of choice has become more widespread 16,19 . We currently treat all of our patients with HBIG for 3 months and subsequently provide lifetime antiviral therapy.…”

Section: Discussionmentioning

confidence: 99%

Utilization of hepatitis B core antibody-positive donor liver grafts

MacConmara

Vachharajani

Wellen

et al. 2012

HPB

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Utilization of hepatitis B core antibody-positive donor liver grafts

MacConmara

Vachharajani

Wellen

et al. 2012

HPB

View full text Add to dashboard Cite

show abstract

“…Resistance to LAM is characterized by the substitution of methionine with valine or isoleucine at residue 204 within the tyrosine-methionine-aspartate-aspartate (YMDD) motif of the viral DNA polymerase [4][5] . Adefovir dipivoxil (ADV) is a potent nucleotide analogue against both the wild-type and LAM-resistant HBV [6][7] , and it has been reported that ADV can prevent and treat recurrences of HBV infection following LT [8][9][10] .…”

Section: Introductionmentioning

confidence: 99%

Development of osteomalacia in a post-liver transplant patient receiving adefovir dipivoxil

Minemura

Tokimitsu²,

Tajiri³

et al. 2010

WJH

View full text Add to dashboard Cite

We report the case of a patient treated with living do norrelated liver transplantation who suffered from osteomalacia during adefovir dipivoxil (ADV)containing antiviral therapy for lamivudineresistant hepatitis B virus infection. The patient had generalized bone pain, with severe hypophosphatemia after 20 mo of ADV therapy. Radiographic studies demonstrated the presence of osteomalacia. The peak plasma ADV level was 38 ng/mL after administration of ADV at 10mg/day. It was also found that ADV affected the metabolism of tacrolimus, a calcineurininhibitor, and caused an increase in the plasma levels of tacrolimus. The disability was reversed with the withdrawal of ADV and with mineral supplementation. ADV can cause an elevation of plasma tacrolimus levels, which may be associated with renal dysfunction. High levels of ADV and tacrolimus can cause nephrotoxicity and osteomalacia. This case highlights the importance of considering a diagnosis of osteomalacia in liver transplantation recipients treated with both ADV and tacrolimus.

show abstract

“…In the transplant setting at large, reported experience with ADV is still very limited . In liver transplant recipients, ADV was consistently shown to reduce viral load and improve liver function and histology in LMV‐resistant patients, with a very good safety profile . In heart and renal transplant, however, there is an almost complete lack of data regarding not only ADV but also the most recently approved and potent antiviral agents with high genetic barrier toward resistance, such as entecavir and tenofovir .…”

Section: Discussionmentioning

confidence: 99%

Adefovir treatment for chronic hepatitis B in heart transplant recipients

Durante‐Mangoni

Iossa

Pinto

et al. 2013

Clinical Transplantation

View full text Add to dashboard Cite

Chronic hepatitis B is prevalent in the transplant setting and may cause significant complications. Effective control of viral replication is needed. Besides lamivudine, very little data are available on safety and efficacy of other drugs. We describe our experience with adefovir dipivoxil (ADV) in eight heart transplant recipients. Studies included a baseline liver biopsy, thrice-monthly clinical, biochemical, and virological evaluations, including genotyping and viral load, polymerase gene sequencing for resistance mutations, liver and kidney function tests, and liver ultrasound. Of eight patients, six had fibrosis score ≤2 and negative HBeAg and seven had hepatitis B virus (HBV) genotype D. Upon ADV start, median HBV-DNA was 5.8 logs IU/mL and alanine aminotransferase (ALT) levels were mostly normal. All patients had prior mild-to-moderate renal functional impairment. Seven of eight patients started ADV after a previous course of lamivudine. Five of these seven patients became HBV-DNA undetectable within eight months. One patient with low baseline viremia started ADV de novo and suppressed HBV-DNA. Median treatment duration was 66 months. ADV daily dose was halved in one patient due to renal function worsening. No ALT flares, hypophosphatemia, liver decompensation, liver cancer, or emergence of resistance was observed. Our data suggest that ADV may be a safe and effective rescue treatment for heart transplant recipients with lamivudine-resistant chronic hepatitis B.

show abstract

Study on the Efficacy and Safety of Adefovir Dipivoxil Treatment in Post–Liver Transplant Patients With Hepatitis B Virus Infection and Lamivudine-Resistant Hepatitis B Virus

Cited by 32 publications

References 15 publications

Utilization of hepatitis B core antibody-positive donor liver grafts

Utilization of hepatitis B core antibody-positive donor liver grafts

Development of osteomalacia in a post-liver transplant patient receiving adefovir dipivoxil

Adefovir treatment for chronic hepatitis B in heart transplant recipients

Contact Info

Product

Resources

About